Argenx updates US efgartigimod filing, shares react to FDA review
25.06.2026 - 13:55:38 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 13:55.
Argenx SE (NL0010832176) on Wednesday reported that the US Food and Drug Administration has accepted its biologics license application for efgartigimod in generalized myasthenia gravis, reinforcing the biotech group’s US regulatory pipeline as its shares trade on Nasdaq.
FDA accepts efgartigimod BLA
Per the company’s investor update dated June 24, 2026, Argenx stated that the FDA has accepted for review its biologics license application (BLA) for intravenous efgartigimod in generalized myasthenia gravis, a chronic autoimmune neuromuscular disease impacting patient mobility and quality of life. The Argenx investor relations page details the BLA acceptance and notes that the agency has set a standard 12-month review timeline for the submission.
The filing builds on the company’s existing US approval for efgartigimod in myasthenia gravis and expands the potential reach of the FcRn-targeting antibody fragment in autoimmune neurology, according to the same communication. Argenx highlighted that it is running several phase 3 programs with efgartigimod in indications such as chronic inflammatory demyelinating polyneuropathy and immune thrombocytopenia, signaling a broader franchise ambition in rare immune-mediated disorders.
Biotech sector backdrop and analyst views
Against the wider biotech sector, Argenx shares have been trading in a volatile pattern on Nasdaq as investors digest both company-specific trial updates and broader swings in risk appetite linked to US interest-rate expectations. A recent market commentary from Reuters on the biotech space noted that high-growth therapeutics names continue to see mixed trading as investors rotate between defensive healthcare and more cyclical sectors. Reuters highlighted cautious sentiment toward growth stocks ahead key inflation data, a context that also frames trading in mid-cap biotech names such as Argenx.
Analyst coverage remains active. According to a recent consensus snapshot referenced by MarketScreener, a majority of covering houses continue to rate Argenx as Buy or Outperform with a focus on efgartigimod’s commercial uptake in existing indications and pipeline risk-reward in new autoimmune diseases. The MarketScreener consensus overview for Argenx lists multiple international brokers as active on the name, including UBS and JPMorgan, and underscores that investors are watching regulatory milestones like the new BLA acceptance closely.
All news and analysis on the Argenx SE shares
Discover more regulatory updates, trial results and analyst reports on Argenx SE, including how efgartigimod shapes the company’s long-term growth profile.
How Argenx generates revenue
Argenx’s core revenue stream comes from the commercialization of efgartigimod, marketed as Vyvgart in several territories, for autoimmune indications such as generalized myasthenia gravis, where it is sold through specialty channels and reimbursed by national health systems and private insurers. The company also earns milestone and royalty income through collaborations with partners in selected markets, while continuing to invest heavily in research and development to broaden the clinical footprint of its FcRn antibody fragment and other pipeline candidates.
Where the stock trades today
Argenx SE shares last traded on Nasdaq at 390.50 US dollars as of 2026-06-25, 13:45.
Argenx SE at a glance
- Company: Argenx SE
- ISIN: NL0010832176
- WKN: A2AS3C
- Ticker: ARGX
- Trading venue: Nasdaq
- Price (as of 2026-06-25, 13:45): 390.50 USD
- Market cap: 22.5 billion USD (as of 2026-06-25)
- Sector / industry: Biotechnology - autoimmune therapeutics
- Index membership: Nasdaq Global Select
- Next earnings date: 2026-07-25
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
